top of page

SAPHRA (ECTD & Human Medicines Unit): Variation Communication Guideline

Writer's picture: Sharan MuruganSharan Murugan

South African Health Products Regulatory Authority (SAHPRA) on 30 September 2022, released updated guidance on " Business As Usual (BAU) Variations Communication".


SAHPRA has adopted the European Union (EU) variation classification guideline, with the full details (including the associated exceptions) published in the Variations Addendum for Human and Veterinary Medicines [2.08].

The purpose of this guidance is to inform applicants on how to submit variations for Category A and C medicines to the SAHPRA as well as what to expect during the review of variation applications.


Type I eSubmission variation applications and eSubmission response submissions should be submitted via the Digital Variations Portal (DVP). Type I eCTD, eCTD response submissions and all Type II variation applications should be submitted via the File Transfer Protocol (FTP).


Applicants can submit "z" code variations to SAHPRA for unforeseen changes not accounted for in the EMA guidelines. Any codes that have not been detailed in the SAHPRA variations addendum should be submitted as a "z" code.


Applicants are to submit "z" code variation requests to the relevant technical unit (Unit Manager & Variations email addresses) and the relevant unit will inform the applicant within 5 working days of the correct application classification and the application fee required, via email.

“z” code submissions cannot be made without obtaining and/or receiving confirmation from SAHPRA.


Click this LINK to know more about SAPHRA's Variations Communication guideline.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page